logo

For the Inventor, By the Inventor

Nes Ziona, Israel

Rami Skaliter

USPTO Granted Patents = 12 

Average Co-Inventor Count = 2.8

ph-index = 5

Forward Citations = 132(Granted Patents)


Location History:

  • Ness-Ziona, IL (2002 - 2007)
  • Nes Ziona, IL (2002 - 2015)

Company Filing History:

goldMedal6 out of 13 
 
Quark Biotech, Inc.
 patents
silverMedal6 out of 67 
 
Quark Pharmaceuticals, Inc.
 patents
bronzeMedal1 out of 5 
 
Silence Therapeutics Ag
 patents
where one patent can have more than one assignee

Years Active: 2002-2015

Loading Chart...
12 patents (USPTO):Explore Patents
1. 9056903 - Therapeutic uses of inhibitors of RTP801 (2015-06-16),
2. 8614309 - Double-stranded RNA directed to CASP2 and methods of use thereof (2013-12-24),
3. 8067570 - Therapeutic uses of inhibitors of RTP801 (2011-11-29),
4. 7973156 - Hypoxia-regulated genes (2011-07-05),
5. 7872119 - Inhibitors of RTP801 and their use in disease treatment (2011-01-18),
6. 7524935 - Sequences characteristic of hypoxia-regulated gene transcription (2009-04-28),
7. 7259253 - Genes associated with mechanical stress, expression products therefrom, and uses thereof (2007-08-21),
8. 7074895 - Sequences characteristic of hypoxia-regulated gene transcription (2006-07-11),
9. 6740738 - Antibody against hypoxia proteins (2004-05-25),
10. 6555667 - Hypoxia-regulated genes (2003-04-29),
11. 6455674 - Hypoxia-regulated genes (2002-09-24),
12. 6403316 - Isolation of cDNA encoding for secreted or membranal proteins (2002-06-11),

Title: The Innovative Mind of Rami Skaliter

Introduction

Rami Skaliter, an accomplished inventor based in Nes Ziona, Israel, has made significant contributions to the field of biotechnology. With a notable record of 12 patents, he has focused his work on developing innovative solutions for various medical conditions, particularly in the realm of gene therapy and therapeutic applications.

Latest Patents

Among his latest inventions, Rami Skaliter has patented the "Therapeutic uses of inhibitors of RTP801." This groundbreaking invention introduces novel molecules and methods tailored for treating microvascular disorders, eye diseases, respiratory conditions, and hearing disorders through the inhibition of the RTP801 gene and/or protein.

Additionally, he has developed a patent for "Double-stranded RNA directed to CASP2 and methods of use thereof." This invention encompasses siRNA compounds with innovative sequences and structural motifs designed to down-regulate the expression of specific human genes. The patent further includes pharmaceutical compositions featuring these compounds and methods for treating or preventing various diseases related to the target genes.

Career Highlights

Rami Skaliter has had an impactful career with positions in prominent companies such as Quark Biotech, Inc. and Quark Pharmaceuticals, Inc. His work in these organizations has allowed him to collaborate on pioneering projects aimed at advancing medical treatments and enhancing the understanding of gene therapy.

Collaborations

Throughout his career, Rami has worked alongside esteemed colleagues such as Paz Einat and Elena Feinstein. These collaborations have played a significant role in shaping his research and innovations, contributing to the successful development of his patents and the impact of his inventions in the biotechnology field.

Conclusion

In summary, Rami Skaliter stands out as a visionary inventor whose dedication to innovation has the potential to transform medical treatments. His extensive patent portfolio reflects a commitment to improving health outcomes and advancing scientific knowledge in the areas of gene therapy and biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…